Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Insulin degludec (Tresiba) is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. It demonstrates comparable efficacy to insulin glargine regarding the mean change in HbA1c levels and incidence rates of hypoglycemia but offers superior reduction in fasting plasma glucose.
• The analysis was based on a review of 19 systematic reviews/meta-analyses focused on Tresiba's safety and effectiveness compared to other insulin analogues across various patient populations.
• When combined with GLP-1 receptor agonist liraglutide (IDegLira), insulin degludec shows significant improvements in glycemic control for Type 2 Diabetes patients, including better HbA1c reduction without weight gain or severe hypoglycemia.
• Compared to newly introduced ultra-long-action basal insulins like Insulin Icodec, Tresiba has shown superior efficacy, particularly when considering HbA1C reduction and safety profiles according to subgroup analyses.
• Across different patient populations such as those with Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D), Tresiba generally presents a favorable safety profile by reducing the risk of hypoglycemia compared to other insulin analogs like Glargine and Detemir.
• Several studies suggest that Tresiba may be less likely than other therapies to cause weight gain while offering convenient dosing regimens that could potentially enhance overall management of diabetes.
• The drug's benefits extend from adolescent through elderly patients, indicating its broad applicability for both Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D).
• Specific comparisons between Tresiba (Insulin Degludec) and drugs such as IGlar-300 or novel Insulin Icodec reveal nuanced differences that might guide personalized treatment decisions, especially concerning hypoglycemia risk and dosing frequency preferences.